TABLE 2.

CNA of target genes and clinical characteristics.

Characteristics	FBN1			FN1			HGF
	n	c	P	n	c	P	n	c	P
T1	15	4	0.076	11	8	0.065	8	11	0.321
T2	49	31		63	17		41	39
T3	104	63		109	58		77	90
T4	75	25		75	25		57	43
T1+2	64	35	0.667	74	25	0.277	49	50	0.906
T3+4	179	88		184	83		134	133
N0	81	31	0.208	76	36	0.540	54	58	0.253
N1	65	32		73	24		56	41
N2	43	32		54	21		32	43
N3	49	25		49	25		37	37
N0+1	146	63	0.109	149	60	0.658	110	99	0.238
N2+3	92	57		103	46		69	80
M0	222	107	0.535	233	96	0.765	161	168	0.286
M1	16	10		17	8		15	10
Stage1	35	18	0.350	36	17	0.851	24	29	0.702
Stage2	80	30		75	35		55	55
Stage3	93	57		109	41		75	75
Stage4	25	13		27	11		22	16
Stage1+2	115	48	0.124	111	52	0.385	79	84	0.559
Stage3+4	118	70		136	52		97	91
G1	7	3	0.256	8	2	0.162	4	6	0.306
G2	84	53		89	48		61	76
G3	152	66		161	57		114	104
Female	88	46	0.825	89	45	0.158	74	60	0.096
Male	161	79		176	64		111	129
Characteristics	MMP9			THBS1			VCAN
	n	c	P	n	c	P	n	c	P
T1	5	14	0.620	13	6	0.180	10	9	0.212
T2	25	55		95	32		47	33
T3	50	117		105	62		87	80
T4	37	63		70	30		65	35
T1+2	30	69	0.678	108	38	0.078	57	42	0.912
T3+4	87	180		175	92		152	115
N0	41	71	0.433	78	34	0.190	67	45	0.473
N1	27	70		65	32		50	47
N2	21	54		41	34		41	34
N3	26	48		47	27		46	28
N0+1	68	141	0.83	143	66	0.068	117	92	0.650
N2+3	47	102		88	61		87	62
M0	105	224	0.673	214	115	0.916	185	144	0.450
M1	9	16		16	9		16	9
Stage1	16	36	0.663	34	19	0.336	31	22	0.665
Stage2	39	71		79	32		60	50
Stage3	45	109		91	59		84	66
Stage4	14	24		23	15		25	13
Stage1+2	55	107	0.518	113	51	0.106	91	72	0.685
Stage3+4	59	133		114	74		109	79
G1	1	10	0*	7	3	0.023*	7	3	0*
G2	31	106		76	62		58	79
G3	84	134		151	67		141	77
Female	54	80	0.009*	87	47	0.883	81	53	0.272
Male	65	175		154	86		131	109

* Indicates p < 0.05; “n” meant non-CNA group; “c” meant CNA group.